#China #Shanghai #Wee Joo Chng #Asian Myeloma Network #IMFG

Dr. Wee Joo Chng to Receive Prestigious Recognition at the AMN Summit in Shanghai

The International Myeloma Foundation (IMF) is pleased to announce that Dr. Wee Joo Chng will be honored with the Asian Myeloma Network Distinguished Service Award at the upcoming 10th Annual AMN Summit. This recognition will take place on October 17, 2026, during the awards ceremony in Shanghai, China, which will occur as part of the largest gathering of myeloma specialists in Asia.

Dr. Chng’s exemplary contributions to myeloma research and patient care align seamlessly with the mission of the Distinguished Service Award, which honors individuals for their significant impact on the myeloma community. This award was formally established by the AMN Executive Committee in 2023 to acknowledge the lifetime achievements of specialists in the myeloma field.

Currently serving as the Chairman of the Asian Myeloma Network (AMN), Dr. Chng has played a pivotal role in advancing research and patient initiatives. He holds esteemed positions such as the Vice President of Biomedical Sciences Research at the National University of Singapore and the Yong Loo Lin Professor in Medical Oncology at the Yong Loo Lin School of Medicine.

Dr. Chng graduated from the University of Leeds, UK, and specialized in hematology in Singapore. His proficiency in employing high-resolution genomic techniques for translational research has revolutionized the understanding of hematological malignancies, particularly in identifying drug targets and improving treatment outcomes.

His work has not gone unrecognized; Dr. Chng’s accolades include the Brian G.M. Durie Outstanding Achievement Award and the Yong Loo Lin School of Medicine Graduate Mentor of the Year Award. His extensive list of publications in prominent journals demonstrates his lasting influence in the field of myeloma.

Dr. Chng expressed his gratitude upon receiving the award, stating: "It is truly a privilege to lead the AMN and contribute to improving the lives of myeloma patients in Asia. I am passionate about mentoring the next generation of myeloma experts and amplifying the voices of patients across the region. This recognition only motivates me further to continue our work."

The importance of Dr. Chng’s contributions cannot be overstated. He has fostered a collaborative spirit among healthcare providers, researchers, and educators in the myeloma community. According to S. Vincent Rajkumar, MD, Chair of the International Myeloma Working Group, Dr. Chng's efforts have established a robust platform for enhancing patient care and clinical research throughout Asia.

As the AMN Distinguished Service Award ceremony approaches, attention is drawn to the collaborative efforts surrounding myeloma research and patient advocacy. Daniel Navid, IMF Senior Vice President of Global Affairs, emphasized the award's role in highlighting the advancements and contributions made by individuals like Dr. Chng, which directly benefit the myeloma patient community.

With the AMN Summit set to facilitate significant discourse among professionals, it also reflects on the broader implications of myeloma treatment advancements and research innovations. Established in 1990, the IMF remains committed to accelerating myeloma prevention and improving quality of life for affected individuals worldwide.

For more information about the Asian Myeloma Network and the AMN Summit, please visit myeloma.org/asian-myeloma-network. Keep an eye out for further developments as Dr. Chng continues to lead initiatives aimed at transforming myeloma treatment and patient support.

About Multiple Myeloma

Multiple myeloma is a severe form of cancer affecting plasma cells in the bone marrow, leading to multiple health complications including bone and kidney damage. Although currently incurable, significant advancements in survival rates have been observed over the past two decades. Myeloma is notably more prevalent and diagnosed at a younger age among African Americans compared to other demographics. Symptoms typically include fatigue and bone pain, underscoring the need for community awareness and patient support.

About the International Myeloma Foundation

Founded in 1990, the International Myeloma Foundation (IMF) is a leading organization dedicated to combating myeloma through world-class research, education, advocacy, and support services for affected individuals and their families. Through its global efforts, the IMF ensures that scientific advances translate into better patient care, advocacy, and empowerment for those navigating the challenges of living with myeloma.